Shared genetic architecture between phenotypes may be driven by a common genetic basis (pleiotropy) or a subset of genetically similar individuals (heterogeneity). We developed BUHMBOX, a well-powered statistical method to distinguish pleiotropy from heterogeneity using genotype data. We observed a shared genetic basis between 11 of 17 tested autoimmune diseases and type I diabetes (T1D, p<10 -12 ) and 11 of 17 tested autoimmune diseases and rheumatoid arthritis (RA, -9 ). This sharing is not explained by heterogeneity (p BUHMBOX =0.28 in 9,238 MDD cases).
genetic features in autoimmunity are due to pleiotropy. We observed a shared genetic basis between seronegative and seropostive RA (p<10 -22 ), explained by heterogeneity (p BUHMBOX =0.008 in 2,406 seronegative RA cases). Consistent with previous observations, we observed genetic sharing between major depressive disorder (MDD) and schizophrenia (p<10 -9 ). This sharing is not explained by heterogeneity (p BUHMBOX =0.28 in 9,238 MDD cases).
INTRODUCTION
Recent studies have demonstrated that many diseases share risk alleles [1] [2] [3] [4] and exhibit significant coheritability [5] [6] [7] . Traditional approaches for detecting coheritability include twin or family studies 8, 9 . Now alternative approaches using genome-wide association study (GWAS) data from unrelated individuals have been developed. Polygenic risk score approaches 3, 10, 11 build genetic risk scores (GRSs) for one phenotype and test their association with a second phenotype. Mixed-model approaches 5, 6, 12 can estimate the genetic covariance between two traits on the observed scale. From the genetic covariance one can also calculate the genetic coheritability and genetic correlation 6 . Cross-trait LD Score regression utilizes linkage disequilibrium (LD) and summary statistics obtained from GWAS to estimate genetic correlation attributable to SNPs 7 . In addition, the p-values of independent SNPs associated with multiple phenotypes can be tested for a significant deviation from the null distribution 2 . These approaches have been applied to demonstrate significant shared genetic structure among many phenotypes 5, 7, 13 including autoimmune 2 and neuropsychiatric diseases 3, 6, 11 . Coheritability and genetic sharing suggests the possibility of pleiotropy, defined here as the sharing of risk alleles across traits at specific genetic variants or at a genome-wide level. Pleiotropy can occur when the same variant causes different diseases (biological pleiotropy, e.g. variant R620W in PTPN22 is associated with multiple autoimmune diseases) 14 , or when a variant causes development of a phenotype that then drives the development of a second phenotype (mediated pleiotropy, e.g. rare coding region variants in LDLR that increase LDL cholesterol levels are associated with increased risk of myocardial infarction) 15 .
However, it remains uncertain whether the observed shared genetic structure is the consequence of true pleiotropy, or the consequence of heterogeneity. Here, we define heterogeneity as the situation where a patient cohort consists of genetically distinct subgroups that may or may not result in distinct symptom profiles and treatment outcomes. This type of Han, Pouget, et al.
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heterogeneity can occur in the context of misclassifications (e.g. cases with atypical presentation for a different disease are erroneously included), molecular subtypes (e.g. a subset of cases share pathogenesis with a different disease, possibly as a result of biological or mediated pleiotropy), or ascertainment bias (e.g. cases also affected with a different disease are more likely to come to clinical attention and be included in the study). These situations can result in a subgroup of cases that is genetically similar to another disease, creating shared genetic structure. Indeed, there is mounting evidence that misclassifications [16] [17] [18] [19] , etiological diversity 20 , and ascertainment bias 21 are prevalent across certain human diseases, leading to the conclusion that significant heterogeneity may exist [22] [23] [24] [25] . Since the potential contribution of heterogeneity to any genetic sharing observed between diseases represents a critical component of predictive medicine, there is a need for statistical methods to detect heterogeneity on the basis of commonly available genetic data. Figure 1) .
RESULTS

Overview of BUHMBOX
Finally, to evaluate BUHMBOX's power to detect heterogeneity we repeated the above simulations assuming there was no pleiotropy, but that there was indeed subtle heterogeneity.
Specifically we assumed that 10% of D A cases were actually D B (π=0.1). Here, BUHMBOX demonstrated 91.1% power to detect heterogeneity at p<0.05 (Supplementary Figure 1) . The GRS approach demonstrated 100% power to detect shared genetic structure.
Together, these simulations illustrate that BUHMBOX is sensitive to heterogeneity but robust to the presence of pleiotropy, while the GRS detects both scenarios and cannot discriminate between the two. BUHMBOX complements existing methods for detecting pleiotropy by helping to interpret shared genetic structure identified with these approaches (Supplementary Table 1 ).
Weighting SNPs by their effect sizes increases power
BUHMBOX combines multiple correlations into one statistic. In order to maximize power, we defined a scheme to weight the correlations between alleles as a function of their effect sizes and allele frequencies (Methods). In simulations we observed substantial power gain with this weighting scheme. Assuming 1,000 cases and 50 loci, we compared the power of BUHMBOX implemented with and without weighting correlations (equation (12) 
Controlling for linkage disequilibrium
Although BUHMBOX adequately controlled the FPR when loci were truly independent, we were concerned that long-range LD between two apparently independent loci may introduce false positives 27 . To ensure that BUHMBOX was robust to the effects of LD, we implemented the following strategies in BUHMBOX: (1) stringent LD-pruning of the set of D B loci to exclude SNPs within 1Mb of each other and those with r 2 >0.1, and (2) accounting for any residual LD after pruning by assessing the relative increase of correlations in cases compared to controls (deltaHan, Pouget, et al.
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We evaluated the effectiveness of these strategies by measuring FPR using the RA Immunochip Consortium data 28 . We generated 1,000 different loosely pruned (r 2 <0.5) SNP sets using the Sweden EIRA data (Methods) and measured the FPR without using deltacorrelations. As expected, we observed a high FPR (25.2%) at p<0.05. However, when we repeated simulations using stringent pruning (r 2 <0.1) and delta-correlations, we were able to conservatively control the FPR (FPR=0.022) at p<0.05.
Accounting for population stratification
Another potential confounding factor that can challenge independence across loci is population 28 (Methods) to create a highly stratified dataset. We then randomly sampled 1,000 sets of independent SNPs from this sample. We observed an inflation of the FPR (8.6% at p<0.05), which was appropriately corrected (5.9% at p<0.05) when we regressed out the effect of ten PCs.
Han, Pouget, et al. Table   4) . We considered only these traits for subsequent analyses.
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Application to autoimmune diseases
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To evaluate the degree of heterogeneity necessary to achieve the observed genetic sharing for these autoimmune diseases, we calculated the GRS regression coefficient. We previously showed that the GRS regression coefficient approximates the expected heterogeneity proportion π 36 assuming no pleiotropy. Based on the GRS coefficients, we observed π estimates ranging from 8-76% across the different autoimmune diseases in T1D and from 10-43%
with RA ( Figure 4 , Table 1 ).
We then estimated the power of BUHMBOX to detect heterogeneity, using Bonferroni correction for 11 tests (p<4.5x10 -3 ). We found that BUHMBOX is well powered for some autoimmune traits.
Assuming π =0.2, four traits had >90% power for T1D, and four traits had >90% power for RA ( Figure 5 ). Despite high power for certain traits, we observed no evidence of heterogeneity at all (corrected p>0.2; Figure 6 , Table 3 
Application to major depressive disorder and schizophrenia
Current criteria for diagnosing psychiatric disorders reflect clinical syndromes, often with overlapping symptoms. As a result, psychiatric diagnoses for a patient may change as their symptoms evolves. MDD is thought to be a particularly heterogeneous psychiatric disorder, with relatively low diagnostic stability 19 . In addition to the potential for misdiagnosis, a subset of true MDD cases may be genetically more similar to schizophrenia. If heterogeneity with respect to schizophrenia risk alleles exists among MDD cases, then genetic studies would suggest evidence of coheritability between the two disorders 37 as has been observed in previous studies 3, 6, 7 . The unintentional inclusion of "schizophrenia-like" MDD cases, due to diagnostic misclassification or genetically distinct subgroups, has been acknowledged and explored as a potential source of bias in coheritability studies by previous investigators 3, 37 .
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We used BUHMBOX to test for a subgroup of "schizophrenia-like" cases in MDD. Supplementary Table 5 for details of the MDD dataset). Consistent with previous findings 3, 6 , the GRS based on these loci was significantly associated with MDD case status (p=1.54 x 10 -5 ) indicating shared genetic structure between schizophrenia and MDD (Figure 4) . For the GRS analysis we used a refined subset of the total sample (6,382 MDD cases and 5,614 controls), which excluded samples that overlapped with the schizophrenia However, we note that we did not have adequate statistical power to detect heterogeneity in the context of a small degree of heterogeneity. Given the MDD sample size and the number of currently known schizophrenia risk loci, there was 53% power to detect 20% heterogeneity, but only 25% power to detect 10% heterogeneity ( Figure 5 ).
DISCUSSION
Here we present BUHMBOX, which can distinguish whether shared genetic structure between two traits is the consequence of heterogeneity versus pleiotropy based on SNP genotype data alone. Our method builds upon recent observations emerging in the literature of shared genetic structures in autoimmune, neuropsychiatric, and metabolic diseases. BUHMBOX utilizes the intuition that if heterogeneity exists, independent loci will show non-random positive correlations;
importantly, we correct for population structure and long-range LD, which may serve as confounders for this analysis. Heterogeneity can be caused by (1) misdiagnosis, (2) a subgroup of cases that share molecular etiology with another disease, or (3) an excessive number of cases affected by comorbidity compared to what would be expected under pleiotropy alone, which can happen because of ascertainment bias or causal relationships between diseases (i.e. mediated pleiotropy in a subgroup of cases). We emphasize that it is critical to appropriately interpret the source of heterogeneity, which will depend on the biological and clinical relationship between the two traits. We provide detailed information to guide interpretation in the Supplementary Information.
We demonstrated that much of the genetic sharing between autoimmune diseases is due to pleiotropy. We do note that for a few traits we had modest power ( Figure 5 ) to detect heterogeneity proportions less than π =0.2. One exception was our analysis that suggested that seronegative RA samples might contain misclassified seropositive RA cases. In contrast we were underpowered to draw a definitive conclusion as to whether a subset of MDD cases are genetically similar to schizophrenia cases, although undoubtedly as MDD cohorts increase in size we will be able to reassess more accurately whether smaller proportions of heterogeneity might partially explain the observed coheritability. Our current results are in line with the results of an analytical study 37 , which concluded that the observed degree of pleiotropy between psychiatric diseases is unlikely explained by misclassifications alone.
We have shown that the power of BUHMBOX is a function of sample size, number of loci, effect sizes and allele frequencies of loci, and the heterogeneity proportion π . For detecting subtle heterogeneity (π <0.1), current datasets were often not well powered. But, we expect that in future studies, as we increase the sample size as well as the number of known associated loci, our method will become increasingly powerful for detecting subtle heterogeneity. Even with existing genetic data, a potential strategy to augment power is to include a larger number of SNPs selected using less stringent significance thresholds, an approach referred to as polygenic modeling 3, 10, 11 . We performed simulations to demonstrate that polygenic modeling can indeed increase the power substantially (Supplementary Methods and Supplementary
Figure 2).
We designed BUHMBOX to identify the presence of heterogeneity, in the situation where we do not know the specific membership of individuals to the subgroup. In this paper, it was not our goal to uncover subgroup membership using genetic data, because genetic information is typically not adequate to clearly classify individuals into subgroups. In certain situations, we may be able to discern membership. For example, for the misclassification of seropositive RA samples in the seronegative RA cohort, as serological assays advance we will have a means to more precisely define membership 40 . If we know the membership, it is possible to perform additional analyses such as comparing GRS between subgroups.
When comparing BUHMBOX to existing approaches, we focused on the GRS method.
However, the results of our comparison also apply to other existing methods such as mixedmodel-based approaches 5, 6 and LD-score-based approaches 7 , which are similar to the GRS approach in the sense that they detect both pleiotropy and heterogeneity. We expect that BUHMBOX will complement any of these methods to facilitate interpretation of observed genetic sharing between traits. More broadly, BUHMBOX can be thought of as capturing a specific form of epistasis where risk alleles correlate positively within the additive model. Our statistical approach may therefore be extended to have application beyond heterogeneity, including identification of missing heritability resulting from clinical heterogeneity 41 . These applications will become more feasible as functional annotations of SNPs advance in the coming years.
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Genetic risk score approach
Given M independent risk loci associated to D B , we calculated the GRS of individual i as 
‫ܩ‬
The BUHMBOX approach
To detect heterogeneity, we developed the following procedure: and p for the other subgroup (N(1-π) individuals), because Nπ individuals can be thought of as D B cases. Within each subgroup, we generated genotypes assuming that the risk alleles are distributed according to the Hardy-Weinberg equilibrium (HWE) and that the risk loci are independent. We assume HWE in cases because we assume an additive disease model. Then we applied our method to calculate the p-value. We repeated this 1,000 times to approximate power as the proportion of the repeats whose p-values were ≤ 0.05. We evaluated power for different values of N, M, and
Under the assumption that the loci are independent, the false positive rate simulation was equivalent to the power simulation described above with the only difference being that π was set to zero, which forced the null hypothesis. We measured false positive rate by assuming N=1,000 and M=20, and constructing 1,000,000 such studies.
Linkage disequilibrium simulations
To simulate realistic LD, we used chromosome 22 data from control individuals in the Swedish EIRA cohort of the RA dataset (2,762 cases/1,940 controls) 28 . Then, we assigned half of control individuals as cases and the rest as controls. To generate 1,000 random datasets, we thinned the data by 10-fold with different seed numbers using PLINK 44 (with the command --thin 0.1).
We then pruned each of the 1,000 datasets using PLINK 44 with r 2 criterion of 0.5 or 0.1.
Population stratification simulations
To simulate population stratification, we combined HapMap 29 release 23 data (60 CEU founders, 60 YRI founders, and 90 JPT+CHB founders). We set CEU+YRI as cases and JPT+CHB as controls. We calculated PCs after LD pruning r 2 <0.1. We randomly selected 5,000 sets of 22 independent SNPs, each of which was selected from each autosome. We also combined a Northern Europe RA cohort (Swedish EIRA; 2,762 cases/1,940 controls) and a Southern Europe cohort (Spain; 807 cases/399 controls) from the RA dataset 28 . Similar to the linkage disequilibrium simulation, we thinned the chromosome 22 data by 10-fold using 1,000 different random seeds, and applied pruning with criterion r 2 <0.1. Table 3 ). When a locus was not in the Immunochip datasets, we looked for proxy (r 2 >0.2) based on the 10000 Genomes data.
Application to specific phenotypes
Major depressive disorder dataset. We used BUHMBOX to investigate the relationship between MDD and schizophrenia, which have been previously reported to share genetic etiology based on polygenic risk scoring 3 and coheritability analyses 6 . The full MDD sample analyzed comprised nine GWAS datasets collected from eight separate studies (Supplementary Table   5 ) as previously described 39 . All samples were collected through institutional review board approved protocols were collected with consent. For the GRS analysis, individual MDD samples (four cases, 886 controls) that overlapped with those in the schizophrenia GWAS 38 were removed from the analysis; three GWAS cohorts with an insufficient number of independent control samples (n < 5) were also removed from the analysis. GRS analyses were conducted in each of the remaining six GWAS datasets (Supplementary Supplementary Table 3 for a detailed list of SNPs). 
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